论文部分内容阅读
目的:探讨丝裂霉素C(mitomycin C,MMC)在准分子激光原位角膜磨镶术(laserin situkeratomileusis,LASIK)术后角膜上皮植入手术治疗中应用的临床疗效。方法:在31例31眼LASIK术后角膜上皮植入患者手术治疗中应用0.2g/L MMC,观察术后裸眼视力及角膜瓣愈合情况。结果:术后6mo裸眼视力平均为0.82±0.19,较术前明显提高(P<0.05)。绝大部分患者角膜瓣愈合良好,4例患者角膜瓣边缘部分融解,但中心视力无明显影响。结论:在LASIK术后角膜上皮植入手术治疗中应用0.2g/LMMC可以取得良好的临床疗效。
Objective: To investigate the clinical efficacy of mitomycin C (MMC) in the surgical treatment of corneal epithelial implantation after laser in situ keratomileusis (LASIK). Methods: 0.2g / L MMC was used in the surgical treatment of 31 patients with corneal epithelial implantation after 31 eyes. The visual acuity and corneal flap healing were observed. Results: The average visual acuity after 6 months of operation was 0.82 ± 0.19, which was significantly higher than that before operation (P <0.05). Most patients with corneal flap healed well, 4 patients with corneal flap edge melting, but no significant effect of central vision. Conclusion: The application of 0.2g / LMMC in corneal epithelial implantation surgery after LASIK can achieve good clinical curative effect.